partnering

News

White jigsaw pieces on a yellow background

Lilly strikes $1.9bn kidney disease alliance with Ascidian

In its third big licensing deal of the week, Eli Lilly has tapped RNA-editing specialist Ascidian for kidney disease therapies in a $1.9bn alliance.

News

Innovent in line for $10.5bn in Pfizer cancer alliance

Pfizer has signed a strategic-level alliance with Innovent, worth $10.5bn and spanning 12 cancer assets, in another sign of China's rising R&D status.

News

Newel Health, Gerresheimer team up to help pharma embrace di...

Newel Health and Gerresheimer ally to help pharma firms embed digital endpoints, real-world data, and AI into clinical testing and commercialisation.

News

Tuneable peptide biotech Parabilis files IPO

Fresh from agreeing a wide-ranging alliance with Regeneron worth up to $2.3bn, Parabilis has joined the IPO queue.

News

Bristol Myers Squibb and Hengrui Pharma logos

BMS signs $15.2bn R&D alliance with China's Hengrui

Hengrui agrees a $15.2bn R&D alliance with BMS in oncology/haematology and immunology, less than a year after a similar $12bn deal with GSK.

News

GSK enlists local aid for Chinese rollout of hep B drug

GSK has partnered Sino Biopharm to make the most of the Chinese launch of hepatitis B drug bepirovirsen, currently under NMPA review.

Lilly strikes $1.9bn kidney disease alliance with Ascidian

Innovent in line for $10.5bn in Pfizer cancer alliance

Newel Health, Gerresheimer team up to help pharma embrace di...

Tuneable peptide biotech Parabilis files IPO

BMS signs $15.2bn R&D alliance with China's Hengrui

GSK enlists local aid for Chinese rollout of hep B drug

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

partnering

Editor's Picks